Background: Obesity rates are increasing day by day affecting all populations at different ages. The most prevalent kind of cancer among women worldwide is breast cancer, with increasing rates in the present time and in the future. Substantial connections between obesity and breast cancer are demonstrated. Elevated circulating levels of insulin and interleukin-6 have a substantial link to obesity and breast cancer development.
Objective: This study aimed to examine the serum levels of insulin and interleukin-6 in postmenopausal breast cancer patients and to study the connection between these biomarkers and breast cancer development.
Method: In this research, 120 postmenopausal women actively participated., 30 had a body mass index of >30kg/m2 diagnosed with breast cancer and considered as obese (group 1), 30 with a body mass index of <30kg/m2 with breast cancer and considered as not obese (group 2), 30 had a body mass index of >30 kg/m2 who were apparently healthy and were obese (group 3), and 30 participants with a body mass index of <30 kg/m2 , were apparently healthy and were not obese (group 4). Five millilitres of venous blood were provided by each individual. Insulin and interleukin-6 levels in the blood were measured using ELISA (enzyme-linked immunosorbent assay) kits.
Results: Serum insulin levels were higher in the groups of obese participants (groups 1 and 3) than the groups of non-obese participants (groups 2 and 4), serum levels of interleukin-6 were the lowest in the healthy control group without obesity (group 4). Substantial moderate correlation was found between body mass index and both insulin and interleukin-6. Postmenopausal breast cancer risk is increased with elevations of serum insulin and interleukin-6.
Conclusions: Elevated levels of serum interleukin-6 and insulin were linked to higher body mass index. In addition, in addition interleukin-6 elevated levels were linked to the cancer state of the non-obese patients. Risk of breast cancer increased with higher levels of circulating insulin and intereukin-6.
Received: Mar,, 2023
Accepted: May, 2023
Published: Jan.2023
